Transcode Therapeutics RNAZ
NASDAQ RNAZ
$1.73 +0.05 (+2.55%)
As of: Oct 21, 2026 · 10:02 AM EDT

Transcode Therapeutics (RNAZ) Operating Leases (2023)

Updated

Transcode Therapeutics (RNAZ) posted Operating Leases of $38,291 for Q4 2023, down 79.8% from the prior quarter.

Analysis

Transcode Therapeutics (RNAZ) Operating Leases (2023) Analysis & Trends

Since Q1 2023, Transcode Therapeutics has reported Operating Leases for 4 quarters.

  • According to Business Quant data, Operating Leases for the three prior quarters was $189,766 (Q3 2023), $265,652 (Q2 2023) and $377,813 (Q1 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.25 Bn 1,104.84 Bn 19.71 Bn
2 Johnson & Johnson 615.56 Bn 534.09 Bn 17.26 Bn
3 AbbVie 506.32 Bn 479.44 Bn 12.70 Bn
4 Merck 367.72 Bn 322.10 Bn 12.21 Bn
5 Novartis Ag 298.15 Bn 262.14 Bn 11.24 Bn
6 Astrazeneca 262.32 Bn 236.01 Bn 12.86 Bn
7 Amgen 236.40 Bn 191.80 Bn 7.24 Bn
8 Gilead Sciences 191.30 Bn 165.50 Bn 6.22 Bn
9 Pfizer 170.97 Bn 117.62 Bn 10.94 Bn
10 Transcode Therapeutics 1.65 Mn -40.23 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 38,291.00
Sep 30, 2023 189,766.00
Jun 30, 2023 265,652.00
Mar 31, 2023 377,813.00
API Access

Transcode Therapeutics Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=RNAZ&period=max&api_key=YOUR_API_KEY